The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Andrew Smitherman
Pediatrics - Hematology/Oncology
Clinical or Medical
Cancer (Pediatric Cancers)
18-1500